Unknown

Dataset Information

0

The Vulvar Cancer Risk in Differentiated Vulvar Intraepithelial Neoplasia: A Systematic Review.


ABSTRACT: Differentiated vulvar intraepithelial neoplasia (dVIN) is the precursor of human papillomavirus (HPV)-independent vulvar squamous cell carcinoma (VSCC). Given the rare incidence of dVIN, limited information on the exact cancer risk is available. We systematically reviewed the primary and recurrent VSCC risk in patients with dVIN, as well as the time to cancer development. A systematic search was performed up to July 2021 according to the PRISMA guidelines. Five reviewers independently screened articles on title, abstract and full text, followed by critical appraisal of selected articles using the Quality in Prognostic Studies (QUIPS) tool. Of the 455 screened articles, 7 were included for analysis. The absolute risk for primary VSCC in dVIN varied between 33 and 86%, with a median time to progression to VSCC of 9-23 months. The risk of developing recurrent VSCC in dVIN associated VSCC was 32-94%, with a median time to recurrence of 13-32 months. In conclusion, patients with dVIN have a high risk of developing primary and recurrent VSCC with a short time to cancer progression. Increased awareness, timely recognition, aggressive treatment and close follow-up of HPV-independent vulvar conditions including dVIN is therefore strongly recommended.

SUBMITTER: Voss FO 

PROVIDER: S-EPMC8699429 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Vulvar Cancer Risk in Differentiated Vulvar Intraepithelial Neoplasia: A Systematic Review.

Voss Féline O FO   Thuijs Nikki B NB   Vermeulen Ravi F M RFM   Wilthagen Erica A EA   van Beurden Marc M   Bleeker Maaike C G MCG  

Cancers 20211207 24


Differentiated vulvar intraepithelial neoplasia (dVIN) is the precursor of human papillomavirus (HPV)-independent vulvar squamous cell carcinoma (VSCC). Given the rare incidence of dVIN, limited information on the exact cancer risk is available. We systematically reviewed the primary and recurrent VSCC risk in patients with dVIN, as well as the time to cancer development. A systematic search was performed up to July 2021 according to the PRISMA guidelines. Five reviewers independently screened a  ...[more]

Similar Datasets

| S-EPMC7515486 | biostudies-literature
| S-EPMC8048962 | biostudies-literature
| S-EPMC8364542 | biostudies-literature
| S-EPMC4964464 | biostudies-literature
| S-EPMC6267258 | biostudies-literature
| S-EPMC8066509 | biostudies-literature
| S-EPMC4404153 | biostudies-literature
| S-EPMC7078831 | biostudies-literature
| S-EPMC5553114 | biostudies-other
2015-03-25 | GSE66987 | GEO